ARCHIVES

Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 5 | May 27, 2005

Download PDF Visit The Full Archive

Related Articles

Cancer Groups Propose Six Characteristics Of Next FDA Head.

December 19, 2008

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

May 2, 2008

Institute of Medicine Elects 70 Members at Annual Meeting

October 25, 2013

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001

DCE Advisors OK Concepts for Registry, Grants In Breast Cancer

June 25, 1993

NCI To Cut Smoking Intervention Study By 20%, Says Chemoprevention Accrual Has Priority

November 6, 1992